Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities

There are no FDA-approved drugs to mitigate the delayed effects of radiation exposure that may occur after a radiological attack or nuclear accident. To date, angiotensin-converting enzyme inhibitors are one of the most successful candidates for mitigation of hematopoietic, lung, kidney, and brain i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Pharmacol
Glavni autori: Medhora, Meetha, Phadnis, Preeya, Narayanan, Jayashree, Gasperetti, Tracy, Zielonka, Jacek, Moulder, John E., Fish, Brian L., Szabo, Aniko
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2021
Teme:
Pharmacology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8111401/
https://ncbi.nlm.nih.gov/pubmed/33986677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.646076
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items